Vancouver, BC, Canada – Cardiome Pharma Corp., a research - March 27, 2013, Vancouver, BC, Canada – Cardiome Pharma Corp., a research-based biopharmaceutical company, announces changes to the company’s senior management team.
Article continues below
break]
William Hunter, previously interim Chief Executive Officer and Director, has been appointed full time President and Chief Executive Officer.
Prior to Cardiome, Dr. Hunter co-founded Angiotech Pharmaceuticals in 1992 and assumed the position of Chief Executive Officer in 1997 when Angiotech was a venture-stage, private, pre-clinical company. He led Angiotech through 3 rounds of private equity financing, the initial public offering and listing on the Toronto Stock Exchange and NASDAQ. Dr. Hunter, a physician by training, served as a practicing physician in British Columbia for 5 years.
Karim Lalji has been promoted from Senior Vice President of Commercial Affairs to Chief Commercial Officer.
Mr. Lalji has served as Cardiome’s SVP Commercial Affairs since 2007. Prior to Cardiome, Mr. Lalji was previously Vice President of Business Strategy and New Product Commercialization at Sepracor, Inc. A key achievement at Sepracor, Inc. was his leadership in the development and launch of Lunesta (eszopiclone) for the treatment of insomnia.
Mr. Lalji’s earlier experience includes ten years with Merck & Company, where he led several successful product launches including Crixivan for HIV/AIDS and Fosamax Once Weekly for osteoporosis.
Mr. Lalji holds a Science Masters in Health and Policy Management from Harvard University.
Sheila Grant has been hired as Chief Operating Officer.
Ms. Grant was most recently Cardiome’s VP of Product Development, with responsibility for the overall management of the vernakalant IV and oral programs. She has overseen the development of vernakalant from its initial pre-clinical studies through to commercialization.
Ms. Grant’s past roles at Cardiome have included Vice President, Commercial Affairs and Director of Business & Clinical Development. ■
LATEST MOVES FROM Vancouver, BC, Canada – Cardiome Pharma Corp., a research-based biopharmaceutical company, announces changes to the company’s senior management team.[break]
William Hunter, previously interim Chief Executive Officer and Director, has been appointed full time President and Chief Executive Officer.